Track the Immunocore Holdings plc stock price and the full insider trade history of the company, a publicly traded company based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). Market capitalisation: €1.7bn. The latest transaction was reported on 19 February 2026 (Levée d'options). Among the most active insiders: Berman David M. Every trade is free.
19
Insider Decl.
n/a
Thresholds
€2m
1 ops.
Buy Volume
€690,840
3 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Immunocore Holdings plc Buy (bullish), based on 11 analysts. Average price target: US$63.58.
30Σ signal
Buys €2m€690,840 Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 20,567 of 28,799 companies
37.3
score / 100
Value
31
Quality
44
FCF yld-0.9%
Earn yld-2.1%
EV/EBITDA·
ROE-7.1%
Gross mgn99%
Net mgn-8.9%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
4,375 shares@ US$29.8749.5% of flowOrdinary SharesSEC:0001209191-24-001014:0
19 of 19 declarations
About Immunocore Holdings plc
Immunocore Holdings plc is a biopharmaceutical company focused on developing T-cell therapies for treating cancer and other diseases. It is listed on NASDAQ under the ticker IMCR.